Abstract
The availability of combined antiretroviral therapy (cART) has significantly improved the prognosis of HIV infection. To control the infection, patients chronically take different groups of antiretroviral drugs, which can lead to numerous unwanted and toxic effects, as well as potential interactions with other co-administered medications and food. Most available antiretroviral drugs are metabolized by cytochrome P450 enzymes and excreted through various transport proteins, which can undergo multiple genetic changes. Single nucleotide polymorphisms (SNPs) have been research subjects in various fields, including HIV infection. Variations in the genetic makeup of metabolic enzymes and transporters are particularly noteworthy. Objective: This research aimed to provide a review and analysis of the most common gene polymorphisms encoding metabolic enzymes and transporters that are essential for the pharmacokinetics of antiretroviral drugs. Methodology: A literature review was conducted by searching the PubMed and Medline databases from 1998 to 2022. The search was performed using appropriate keywords such as "cytochrome", "antiretroviral", "genotype", "polymorphism", "pharmacogenetic", "pharmacogenomic", "pharmacokinetic", "variant", and "single nucleotide polymorphism" in combination with "human immunodeficiency virus" and "acquired immunodeficiency syndrome". The identified literature was then reviewed and analyzed. Results: The clinically most relevant polymorphisms affecting the therapeutic efficacy of antiretroviral drugs include HLA-B5701, CYP2B6 polymorphisms corelated with high plasma concentrations of efavirenz, and UGT1A1*6 and *28 responsible for individual variations in the pharmacokinetics of dolutegravir. Conclusion: Genetic variations, including variations in individual nucleotides, as well as other factors such as gender, coexisting medical conditions, and patient-related factors, play a significant role in therapeutic response. Understanding these factors is of crucial importance for personalized approaches to the treatment of HIV infection and the optimization of therapeutic outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
